세계의 맞춤형 의료 바이오마커 시장(2025-2032년) : 업계 분석, 규모, 점유율, 성장, 동향, 예측

Personalized Medicine Biomarker Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계의 맞춤형 의료 바이오마커 시장 규모는 2025년에 211억 4,880만 달러에 달할 것으로 예상되며, 2025-2032년의 예측 기간 동안 14.2%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 535억 7,340만 달러에 달할 것으로 예측되고 있습니다.

맞춤형 의료 바이오마커 시장은 유전자, 단백질체학 및 대사 프로파일을 기반으로 개별 환자에 맞는 치료를 지원하는 바이오마커의 개발과 이용에 초점을 맞추고 있습니다. 정밀 의료가 점점 더 중요해짐에 따라 임상적 의사결정에서 바이오마커 통합이 크게 이루어지고 있습니다.

세계의 맞춤형 의료 바이오마커 시장의 성장은 몇 가지 유력한 요인에 의해 견인되고 있습니다. 이들 요인은 마커 수요를 더욱 밀어 올리고 있습니다. 또, 차세대 시퀀서(NGS)나 바이오인포매틱스 툴의 진보에 의해 바이오마커에 기반한 진단의 정밀도와 효율이 향상하고 있습니다. 정밀 의료 프로그램을 지원하는 정부의 이니셔티브는 병의 조기 발견에 대한 일반 시민의 의식 증가와 더불어 시장 확장을 촉진하고 있습니다.

이러한 관심과 높은 가능성에도 불구하고 맞춤형 의료 바이오마커 시장은 일정한 억제요인에 직면하고 있습니다. 워크플로우와의 통합 복잡성 외에도 데이터 프라이버시와 유전자 검사와 관련된 윤리적 우려와 관련된 문제도 추가적인 장애물이 되고 있습니다.

맞춤형 의료 바이오마커 시장에는 장기적인 성장을 약속하는 기회가 많이 존재하며 시장 관계자들에게 큰 잠재력을 제공하고 있습니다. 특히 암 영역에서 동반진단 동향 증가는 진단기업과 제약기업과의 새로운 협력의 길을 개척하고 있습니다.

본 보고서는 세계의 맞춤형 의료 바이오마커 시장에 대해 조사했으며, 바이오마커 유형별, 용도별, 적응증별, 최종 사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 범위와 정의
• 시장 역학
• 거시경제 요인
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계의 맞춤형 의료 바이오마커 시장 전망

• 주요 하이라이트
• 시장 규모 분석과 예측
  • 과거 시장 규모 분석(2019-2024년)
  • 현재 시장 규모 분석과 예측(2025-2032년)
• 세계의 맞춤형 의료 바이오마커 시장 전망 : 바이오마커 유형별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 바이오마커 유형별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 바이오마커 유형별(2025-2032년)
  • 시장의 매력 분석 : 바이오마커 유형별
• 세계의 맞춤형 의료 바이오마커 시장 전망 : 용도별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 용도별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 용도별(2025-2032년)
  • 시장의 매력 분석 : 용도별
• 세계의 맞춤형 의료 바이오마커 시장 전망 : 적응증별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 적응증별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 적응증별(2025-2032년)
  • 시장의 매력 분석 : 적응증별
• 세계의 맞춤형 의료 바이오마커 시장 전망 : 최종 사용자별
  • 소개/주요 조사 결과
  • 과거 시장 규모 분석, 최종 사용자별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 최종 사용자별(2025-2032년)
  • 시장의 매력 분석 : 최종 사용자별

제5장 세계의 맞춤형 의료 바이오마커 시장 전망 : 지역별

• 주요 하이라이트
• 과거 시장 규모 분석, 지역별(2019-2024년)
• 현재 시장 규모 분석과 예측, 지역별(2025-2032년)
  • 북미
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 라틴아메리카
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제6장 북미의 맞춤형 의료 바이오마커 시장 전망

제7장 유럽의 맞춤형 의료 바이오마커 시장 전망

제8장 동아시아의 맞춤형 의료 바이오마커 시장 전망

제9장 남아시아 및 오세아니아의 맞춤형 의료 바이오마커 시장 전망

제10장 라틴아메리카의 맞춤형 의료 바이오마커 시장 전망

제11장 중동 및 아프리카의 맞춤형 의료 바이오마커 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
• 기업 프로파일(상세 - 개요, 재무, 전략, 최근 동향)
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Danaher
  • EKF Diagnostics Holdings
  • F. Hoffmann-La Roche
  • Illumina
  • Merck
  • Myriad Genetics
  • QIAGEN
  • Signosis
  • Singulex
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • PerkinElmer Inc.
  • Agilent Technologies, Inc.
  • Meso Scale Diagnostics
  • Enzo Biochem
  • Lifesign LLC
  • Guardant Health
  • Nexus-Dx
  • Proteome Sciences
  • Almac Diagnostics
  • Biocartis

제13장 부록

CSM

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Personalized Medicine Biomarkers Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Personalized Medicine Biomarkers Market Size (2025E): US$ 21,148.8 Mn
• Projected Market Value (2032F): US$ 53,573.4 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 14.2%

Personalized Medicine Biomarkers Market - Report Scope:

The personalized medicine biomarkers market focuses on the development and utilization of biological markers that aid in tailoring medical treatment to individual patients based on their genetic, proteomic, or metabolic profiles. These biomarkers play a critical role in disease diagnosis, treatment selection, drug development, and therapeutic monitoring. With increasing emphasis on precision healthcare, the integration of biomarkers in clinical decision-making has grown substantially. Innovations in genomic technologies, rising demand for targeted therapies, and the growing burden of chronic diseases are key factors accelerating market growth.

Market Growth Drivers:

The growth of the global personalized medicine biomarkers market is being driven by several influential factors. The rapid expansion of genomic and proteomic research, supported by significant investments in biopharmaceutical R&D, is enabling the discovery of novel biomarkers. Rising prevalence of complex diseases such as cancer, diabetes, and neurological disorders is prompting the adoption of personalized treatment strategies, further boosting demand for biomarkers. Additionally, advancements in next-generation sequencing (NGS) and bioinformatics tools are enhancing the accuracy and efficiency of biomarker-based diagnostics. Government initiatives supporting precision medicine programs, coupled with increasing public awareness about early disease detection, are further propelling market expansion.

Market Restraints:

Despite the growing interest and potential, the personalized medicine biomarkers market faces certain restraints. High costs associated with biomarker discovery, validation, and regulatory approvals can hinder widespread adoption, particularly in low- and middle-income regions. The complexity of integrating biomarker-based testing into routine clinical workflows, along with issues related to data privacy and ethical concerns around genetic testing, present additional hurdles. Furthermore, the lack of standardized protocols and inconsistent reimbursement policies across regions can limit market penetration.

Market Opportunities:

There are numerous opportunities within the personalized medicine biomarkers market that promise long-term growth. The increasing use of artificial intelligence and machine learning in biomarker discovery and data analysis is streamlining the development pipeline and improving diagnostic accuracy. Expanding healthcare infrastructure in emerging economies, combined with growing investments in personalized healthcare, offers significant potential for market players. Furthermore, the rising trend of companion diagnostics, particularly in oncology, opens new avenues for collaboration between diagnostic companies and pharmaceutical firms. Strategic partnerships, clinical trial innovations, and investment in multi-omics approaches present further opportunities for market differentiation and expansion.

Key Questions Answered in the Report:

• What are the primary factors driving the global personalized medicine biomarkers market's growth?
• Which biomarker types and applications are gaining the most traction across regions?
• How are technological advancements shaping the future of biomarker-driven diagnostics and treatment?
• Who are the key players in the personalized medicine biomarkers market, and what are their growth strategies?
• What are the major trends, challenges, and opportunities shaping the global market outlook?

Competitive Intelligence and Business Strategy:

Leading companies in the personalized medicine biomarkers market, including Abbott Laboratories, F. Hoffmann-La Roche, Illumina, and QIAGEN, are actively investing in R&D to advance biomarker discovery and develop integrated diagnostic platforms. These players are forming strategic alliances with pharmaceutical companies to co-develop companion diagnostics and personalized treatment solutions. Efforts are also being directed towards expanding biomarker portfolios across diverse disease areas such as oncology, cardiology, and neurology. Focus on clinical validation, regulatory compliance, and cost-effective assay development is enabling companies to strengthen their market positions and cater to evolving healthcare needs.

Companies Covered in This Report:

• Abbott Laboratories
• Bio-Rad Laboratories
• Danaher
• EKF Diagnostics Holdings
• F. Hoffmann-La Roche
• Illumina
• Merck
• Myriad Genetics
• QIAGEN
• Signosis

Market Segmentation:

By Biomarker Type:

• Genomic
• Proteomics
• Metabolic
• Others

By Application:

• Disease Diagnosis
• Drug Discovery & Development
• Therapeutic Monitoring
• Treatment Selection
• Others

By Disease Indication:

• Oncology
• Neurology
• Diabetes
• Autoimmune diseases
• Cardiology
• Others

By End-user:

• Pharmaceutical & Biotechnology Companies
• Hospitals & Clinics
• Diagnostic Laboratories
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Personalized Medicine Biomarkers Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. Macro-Economic Factors
  • 2.3.1. Global Sectorial Outlook
  • 2.3.2. Global GDP Growth Outlook
• 2.4. COVID-19 Impact Analysis
• 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Regulatory Landscape
• 3.2. Product Adoption Analysis
• 3.3. Value Chain Analysis
• 3.4. Key Deals and Mergers
• 3.5. PESTLE Analysis
• 3.6. Porter's Five Force Analysis

4. Global Personalized Medicine Biomarkers Market Outlook:

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Personalized Medicine Biomarkers Market Outlook: Biomarker Type
  • 4.3.1. Introduction / Key Findings
  • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Biomarker Type, 2019-2024
  • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
    • 4.3.3.1. Genomic
    • 4.3.3.2. Proteomics
    • 4.3.3.3. Metabolic
    • 4.3.3.4. Others
  • 4.3.4. Market Attractiveness Analysis: Biomarker Type
• 4.4. Global Personalized Medicine Biomarkers Market Outlook: Application
  • 4.4.1. Introduction / Key Findings
  • 4.4.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2024
  • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
    • 4.4.3.1. Disease Diagnosis
    • 4.4.3.2. Drug Discovery & Development
    • 4.4.3.3. Therapeutic Monitoring
    • 4.4.3.4. Treatment Selection
    • 4.4.3.5. Others
  • 4.4.4. Market Attractiveness Analysis: Application
• 4.5. Global Personalized Medicine Biomarkers Market Outlook: Disease Indication
  • 4.5.1. Introduction / Key Findings
  • 4.5.2. Historical Market Size (US$ Mn) Analysis, By Disease Indication, 2019-2024
  • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 4.5.3.1. Oncology
    • 4.5.3.2. Neurology
    • 4.5.3.3. Diabetes
    • 4.5.3.4. Autoimmune diseases
    • 4.5.3.5. Cardiology
    • 4.5.3.6. Others
  • 4.5.4. Market Attractiveness Analysis: Disease Indication
• 4.6. Global Personalized Medicine Biomarkers Market Outlook: End User
  • 4.6.1. Introduction / Key Findings
  • 4.6.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2024
  • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 4.6.3.1. Pharmaceutical & Biotechnology Companies
    • 4.6.3.2. Hospitals & Clinics
    • 4.6.3.3. Diagnostic Laboratories
    • 4.6.3.4. Others
  • 4.6.4. Market Attractiveness Analysis: End User

5. Global Personalized Medicine Biomarkers Market Outlook: Region

• 5.1. Key Highlights
• 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. East Asia
  • 5.3.4. South Asia and Oceania
  • 5.3.5. Latin America
  • 5.3.6. Middle East & Africa
• 5.4. Market Attractiveness Analysis: Region

6. North America Personalized Medicine Biomarkers Market Outlook:

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.2.1. By Country
  • 6.2.2. By Biomarker Type
  • 6.2.3. By Application
  • 6.2.4. By Disease Indication
  • 6.2.5. By End User
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.3.1. U.S.
  • 6.3.2. Canada
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 6.4.1. Genomic
  • 6.4.2. Proteomics
  • 6.4.3. Metabolic
  • 6.4.4. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 6.5.1. Disease Diagnosis
  • 6.5.2. Drug Discovery & Development
  • 6.5.3. Therapeutic Monitoring
  • 6.5.4. Treatment Selection
  • 6.5.5. Others
• 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 6.6.1. Oncology
  • 6.6.2. Neurology
  • 6.6.3. Diabetes
  • 6.6.4. Autoimmune diseases
  • 6.6.5. Cardiology
  • 6.6.6. Others
• 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 6.7.1. Pharmaceutical & Biotechnology Companies
  • 6.7.2. Hospitals & Clinics
  • 6.7.3. Diagnostic Laboratories
  • 6.7.4. Others
• 6.8. Market Attractiveness Analysis

7. Europe Personalized Medicine Biomarkers Market Outlook:

• 7.1. Key Highlights
• 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.2.1. By Country
  • 7.2.2. By Biomarker Type
  • 7.2.3. By Application
  • 7.2.4. By Disease Indication
  • 7.2.5. By End User
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.3.1. Germany
  • 7.3.2. France
  • 7.3.3. U.K.
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Russia
  • 7.3.7. Turkey
  • 7.3.8. Rest of Europe
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 7.4.1. Genomic
  • 7.4.2. Proteomics
  • 7.4.3. Metabolic
  • 7.4.4. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 7.5.1. Disease Diagnosis
  • 7.5.2. Drug Discovery & Development
  • 7.5.3. Therapeutic Monitoring
  • 7.5.4. Treatment Selection
  • 7.5.5. Others
• 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 7.6.1. Oncology
  • 7.6.2. Neurology
  • 7.6.3. Diabetes
  • 7.6.4. Autoimmune diseases
  • 7.6.5. Cardiology
  • 7.6.6. Others
• 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 7.7.1. Pharmaceutical & Biotechnology Companies
  • 7.7.2. Hospitals & Clinics
  • 7.7.3. Diagnostic Laboratories
  • 7.7.4. Others
• 7.8. Market Attractiveness Analysis

8. East Asia Personalized Medicine Biomarkers Market Outlook:

• 8.1. Key Highlights
• 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.2.1. By Country
  • 8.2.2. By Biomarker Type
  • 8.2.3. By Application
  • 8.2.4. By Disease Indication
  • 8.2.5. By End User
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.3.1. China
  • 8.3.2. Japan
  • 8.3.3. South Korea
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 8.4.1. Genomic
  • 8.4.2. Proteomics
  • 8.4.3. Metabolic
  • 8.4.4. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 8.5.1. Disease Diagnosis
  • 8.5.2. Drug Discovery & Development
  • 8.5.3. Therapeutic Monitoring
  • 8.5.4. Treatment Selection
  • 8.5.5. Others
• 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 8.6.1. Oncology
  • 8.6.2. Neurology
  • 8.6.3. Diabetes
  • 8.6.4. Autoimmune diseases
  • 8.6.5. Cardiology
  • 8.6.6. Others
• 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 8.7.1. Pharmaceutical & Biotechnology Companies
  • 8.7.2. Hospitals & Clinics
  • 8.7.3. Diagnostic Laboratories
  • 8.7.4. Others
• 8.8. Market Attractiveness Analysis

9. South Asia & Oceania Personalized Medicine Biomarkers Market Outlook:

• 9.1. Key Highlights
• 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.2.1. By Country
  • 9.2.2. By Biomarker Type
  • 9.2.3. By Application
  • 9.2.4. By Disease Indication
  • 9.2.5. By End User
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.3.1. India
  • 9.3.2. Southeast Asia
  • 9.3.3. ANZ
  • 9.3.4. Rest of South Asia & Oceania
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 9.4.1. Genomic
  • 9.4.2. Proteomics
  • 9.4.3. Metabolic
  • 9.4.4. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 9.5.1. Disease Diagnosis
  • 9.5.2. Drug Discovery & Development
  • 9.5.3. Therapeutic Monitoring
  • 9.5.4. Treatment Selection
  • 9.5.5. Others
• 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 9.6.1. Oncology
  • 9.6.2. Neurology
  • 9.6.3. Diabetes
  • 9.6.4. Autoimmune diseases
  • 9.6.5. Cardiology
  • 9.6.6. Others
• 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 9.7.1. Pharmaceutical & Biotechnology Companies
  • 9.7.2. Hospitals & Clinics
  • 9.7.3. Diagnostic Laboratories
  • 9.7.4. Others
• 9.8. Market Attractiveness Analysis

10. Latin America Personalized Medicine Biomarkers Market Outlook:

• 10.1. Key Highlights
• 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.2.1. By Country
  • 10.2.2. By Biomarker Type
  • 10.2.3. By Application
  • 10.2.4. By Disease Indication
  • 10.2.5. By End User
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.3.1. Brazil
  • 10.3.2. Mexico
  • 10.3.3. Rest of Latin America
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 10.4.1. Genomic
  • 10.4.2. Proteomics
  • 10.4.3. Metabolic
  • 10.4.4. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 10.5.1. Disease Diagnosis
  • 10.5.2. Drug Discovery & Development
  • 10.5.3. Therapeutic Monitoring
  • 10.5.4. Treatment Selection
  • 10.5.5. Others
• 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 10.6.1. Oncology
  • 10.6.2. Neurology
  • 10.6.3. Diabetes
  • 10.6.4. Autoimmune diseases
  • 10.6.5. Cardiology
  • 10.6.6. Others
• 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 10.7.1. Pharmaceutical & Biotechnology Companies
  • 10.7.2. Hospitals & Clinics
  • 10.7.3. Diagnostic Laboratories
  • 10.7.4. Others
• 10.8. Market Attractiveness Analysis

11. Middle East & Africa Personalized Medicine Biomarkers Market Outlook:

• 11.1. Key Highlights
• 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.2.1. By Country
  • 11.2.2. By Biomarker Type
  • 11.2.3. By Application
  • 11.2.4. By Disease Indication
  • 11.2.5. By End User
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.3.1. GCC Countries
  • 11.3.2. Egypt
  • 11.3.3. South Africa
  • 11.3.4. Northern Africa
  • 11.3.5. Rest of Middle East & Africa
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker Type, 2025-2032
  • 11.4.1. Genomic
  • 11.4.2. Proteomics
  • 11.4.3. Metabolic
  • 11.4.4. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2025-2032
  • 11.5.1. Disease Diagnosis
  • 11.5.2. Drug Discovery & Development
  • 11.5.3. Therapeutic Monitoring
  • 11.5.4. Treatment Selection
  • 11.5.5. Others
• 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 11.6.1. Oncology
  • 11.6.2. Neurology
  • 11.6.3. Diabetes
  • 11.6.4. Autoimmune diseases
  • 11.6.5. Cardiology
  • 11.6.6. Others
• 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
  • 11.7.1. Pharmaceutical & Biotechnology Companies
  • 11.7.2. Hospitals & Clinics
  • 11.7.3. Diagnostic Laboratories
  • 11.7.4. Others
• 11.8. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping By Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Abbott Laboratories
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Products
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Bio-Rad Laboratories
  • 12.3.3. Danaher
  • 12.3.4. EKF Diagnostics Holdings
  • 12.3.5. F. Hoffmann-La Roche
  • 12.3.6. Illumina
  • 12.3.7. Merck
  • 12.3.8. Myriad Genetics
  • 12.3.9. QIAGEN
  • 12.3.10. Signosis
  • 12.3.11. Singulex
  • 12.3.12. Thermo Fisher Scientific
  • 12.3.13. Siemens Healthineers
  • 12.3.14. PerkinElmer Inc.
  • 12.3.15. Agilent Technologies, Inc.
  • 12.3.16. Meso Scale Diagnostics
  • 12.3.17. Enzo Biochem
  • 12.3.18. Lifesign LLC
  • 12.3.19. Guardant Health
  • 12.3.20. Nexus-Dx
  • 12.3.21. Proteome Sciences
  • 12.3.22. Almac Diagnostics
  • 12.3.23. Biocartis

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료